Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Wedbush Remains Sidelined on Fibrocell Science (FCSC) Following Azficel-T Program Failure
June 9, 2016 8:47 AM EDTWedbush maintained a Neutral rating on Fibrocell Science (NASDAQ: FCSC), and cut the price target to $1.50 (from $4.00), as the company reports failure of the azficel-T program. FCSC reported that azficel-T missed the primary endpoints assessing change from baseline at four months in mucosal wave... More
Roth Affirms Fibrocell Science (FCSC) at 'Buy' Following Azficel-T Phase 2 Miss in Vocal Cord Scarring
June 8, 2016 11:59 AM EDTRoth Capital affirms Fibrocell Science, Inc. (Nasdaq: FCSC) at Buy with a price target of $5 after the company announced that primary endpoints were not... More
